- Home
- ACAD vs CWEN Comparison
ACAD vs CWEN Comparison
Compare ACAD & CWEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- CWEN
- Stock Information
- Founded
- ACAD 1993
- CWEN 2012
- Country
- ACAD United States
- CWEN United States
- Employees
- ACAD N/A
- CWEN N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- CWEN Electric Utilities: Central
- Sector
- ACAD Health Care
- CWEN Utilities
- Exchange
- ACAD Nasdaq
- CWEN Nasdaq
- Market Cap
- ACAD 4.3B
- CWEN 3.7B
- IPO Year
- ACAD 2004
- CWEN 2013
- Fundamental
- Price
- ACAD $21.31
- CWEN N/A
- Analyst Decision
- ACAD Buy
- CWEN Buy
- Analyst Count
- ACAD 21
- CWEN 6
- Target Price
- ACAD $29.25
- CWEN $36.00
- AVG Volume (30 Days)
- ACAD 2.3M
- CWEN 1.2M
- Earning Date
- ACAD 11-05-2025
- CWEN 10-29-2025
- Dividend Yield
- ACAD N/A
- CWEN 5.44%
- EPS Growth
- ACAD 615.00
- CWEN N/A
- EPS
- ACAD 1.33
- CWEN 0.64
- Revenue
- ACAD $1,018,885,000.00
- CWEN $1,432,000,000.00
- Revenue This Year
- ACAD $14.01
- CWEN $6.56
- Revenue Next Year
- ACAD $11.81
- CWEN $12.53
- P/E Ratio
- ACAD $16.07
- CWEN $49.82
- Revenue Growth
- ACAD 14.41
- CWEN 14.65
- 52 Week Low
- ACAD $13.40
- CWEN $24.40
- 52 Week High
- ACAD $26.65
- CWEN $33.22
- Technical
- Relative Strength Index (RSI)
- ACAD 33.94
- CWEN 62.39
- Support Level
- ACAD $21.32
- CWEN $27.97
- Resistance Level
- ACAD $21.96
- CWEN $32.48
- Average True Range (ATR)
- ACAD 0.60
- CWEN 0.76
- MACD
- ACAD -0.10
- CWEN 0.43
- Stochastic Oscillator
- ACAD 30.11
- CWEN 74.02
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.